HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A massive block deal unfolded in the pharmaceutical sector as major institutional players shook up the equity structure of Corona Remedies Limited. High-profile investors, including HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA), stepped in to acquire significant stakes during this high-value transaction.
Details of the Massive Divestment
On June 17, 2026, a significant portion of the equity in Corona Remedies was offloaded through a coordinated block deal on the stock exchange. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to the selling pressure, Anchor Partners also participated in the divestment, offloading 1,61,861 shares at the same price of ₹1,730 per share, worth roughly ₹28 crore. When combined, these two entities successfully exited positions worth a total of approximately ₹776.9 crore in the pharmaceutical company.
Institutional Heavyweights Drive the Buy Side
The transaction saw aggressive participation from twelve different institutional investors, signaling strong confidence in Corona Remedies' long-term prospects. HDFC Mutual Fund emerged as the dominant force on the buy side, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value.
Other prominent domestic and international players included:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Acquired 4,50,868 shares for approximately ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares worth about ₹50 crore.
- Kotak Mahindra Mutual Fund: Bought 1,61,861 shares, mirroring the exact quantity sold by Anchor Partners, in a deal worth ₹28 crore.
Global and Specialized Funds Join the Fold
The deal attracted significant interest from global sovereign wealth funds and emerging market specialists. The Abu Dhabi Investment Authority (ADIA) entered the fray by purchasing 39,130 shares valued at ₹6.8 crore.
WhiteOak 生态系统和 Aberdeen 基金也表现出了浓厚的投资意愿。Aberdeen Standard Sicav I - Asian Smaller Companies Fund 投资了约 4.74 亿卢比，而 WhiteOak Capital Mutual Fund 和 Ashoka WhiteOak Emerging Markets Equity Fund 分别购入了价值 2.51 亿卢比和 2.57 亿卢比的股份。Factory Mutual Insurance Company 和 TCW White Oak Emerging Markets Equity Fund 也进行了小规模入股，共同构成了一个由高度专业化的资本提供者组成的多元化群体。
核心要点
- 重大退出： Sepia Investments 和 Anchor Partners 在 Corona Remedies 中累计减持了价值约 77.69 亿卢比的股份。
- HDFC MF 主导地位： HDFC Mutual Fund 是最大的买家，以 42.39 亿卢比的投资额吸收了超过 50% 的总交易额。
- 机构信心： ADIA 等全球巨头以及各类 Aberdeen 和 WhiteOak 基金的参与，凸显了机构在 1,730 卢比这一价格水平下对该公司强烈的兴趣。